The filing of a class action lawsuit typically raises concerns about potential financial liabilities and reputational damage, which can lead to a decrease in investor confidence and a drop in stock price. Given the direct mention of Humacyte and the nature of the news, it is likely to have a negative short-term impact on the stock.